BioLayer assays Prince of Wales
Wednesday, 10 September, 2008
BioLayer Corporation [ASX: BLS] has officially entered into a commercial agreement with the Prince of Wales Medical Research Institute.
The two organisations plan to collaborate on an assay and other diagnostic tools for use in the early detection of neurodegenerative diseases such as Parkinson's.
The companies will share IP to create the new detection tools. Under the agreement, BioLayer has the option to develop existing IP from the Prince of Wales under license.
BioLayer expects to exercise that option early next year.
BioLayer has also filed a patent application for a new approach to protecting assay processes for the early detection of neurodegenerative diseases.
AI-designed DNA switches flip genes on and off
The work creates the opportunity to turn the expression of a gene up or down in just one tissue...
Drug delays tumour growth in models of children's liver cancer
A new drug has been shown to delay the growth of tumours and improve survival in hepatoblastoma,...
Ancient DNA rewrites the stories of those preserved at Pompeii
Researchers have used ancient DNA to challenge long-held assumptions about the inhabitants of...
